Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides

Journal of the National Cancer Institute

Volumn 92, Issue 1, 2000, Pages 34-41

  Miayake, Hideaki ^b   Tolcher, Anthony ^b   Gleave, Martin E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; DNA; MESSENGER RNA; PACLITAXEL; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BCL 2;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; ENZYME DEGRADATION; GENE EXPRESSION; HORMONE RESISTANCE; MALE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 0034606686     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.1.34     Document Type: Article

References (33)

1. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993;72: 3888-95.
2. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998;160:1220-9.
3. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50:2275-82.
4. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A 1986;83:5214-8.
5. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
6. Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
7. Haldar S, Chintapalli J, Croce CM. Paclitaxel induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-5.
8. McDonnell TJ, Troncoso P, Brisby SM, Logothetis CL, Chung LW, Hsieh JT, et al. Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
9. Colombel M, Symmans F, Gil S, O'Toole KM, Choplin D, Benson M, et al. Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
10. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP. Androgen induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995;55:735-8.
11. Raffo AJ, Perlman H, Chen MW, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-45.
12. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localised prostate cancer. J Urol 1996;156:1511-6.
13. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996;56:5594-9.
14. Crooke ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 1992;32:329-76.
15. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996;2:668-75.
16. Zieger A, Luedke GH, Fabbro D, Altman KH, Stahel RA, Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997;89:1027-36.
17. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232-4.
18. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998;78:1035-42.
19. Rennie PS, Bruchovsky N, Buttyan R, Benson M, Cheng H. Gene expression during the early phase of regression of the androgen-dependent Shionogi mouse mammary carcinoma. Cancer Res 1988;48:6309-12.
20. Bruchovsky N, Rennie PS. Classification of dependent and autonomous variants of Shionogi mammary carcinoma based on heterogeneous patterns of androgen binding. Cell 1978;13:272-80.
21. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate-specific antigen levels in mice bearing human prostate LNCaP tumor are determined by tumor volume and endocrine and growth factors. Cancer Res 1992;52:1598-605.
22. Miyake H, Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, et al. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998; 16:933-43.
23. Duska LR, Hamblin MR, Miller JL, Hasan T. Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. J Natl Cancer Inst 1999;91:1557-63.
24. Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T. Bcl-x is phosphorylated in malignant cells following microtubule disruption. Cancer Res 1998;58:3331-8.
25. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994;371:346-7.
26. Saijo Y, Perlaky L, Wang H, Busch H. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol Res 1994;6:243-9.
27. Ollikainen H, Lappalainen K, Jaaskelainen I, Syrjanen S, Pulkki K. Liposomal targeting of bcl-2 antisense oligonucleotides with enhanced stability into human myeloma cell line. Leuk Lymphoma 1996;24:165-74.
28. Campos L, Sabido O, Rouault JP, Guyotat D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994;84:595-600.
29. Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdan M, al-Katib A. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther 1995;2:207-12.
30. Harnois DM, Que FG, Celli A, LaRusso NF, Gores GJ. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology 1997;26:884-90.
31. Zhang X, Jackson JK, Burt HM. Development a amphiphilic diblock copolymers as micellar carriers of paclitaxel. Int J Pharm 1996;132:195-206.
32. Ramaswamy M, Zhang X, Burt HM, Wasan KM. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci 1997;86:460-4.
33. Miyake H, Tolcher A, Gleave ME. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res 1999;59:4030-4.